|
|
Terms and Conditions
Professionals who wish to register to the RESTASIS® (cyclosporine ophthalmic emulsion) 0.05% Professional Web site must provide a valid Medical Education (ME) number. This number is collected to avoid duplication, fraudulent use, or similar misuse, and is solely used for promotional purposes within the framework of the Web site. If the user chooses to end his/her enrollment, the profile and accompanying ME number will be permanently deleted from the Web site and any associated e-mail communication seed lists. Upon registration, the user will be given access to the full Professional Resources section of the Web site. These resources currently include: a listing of links to informational Web sites; an electronic version of the RESTASIS® patient brochure, an informational guide to RESTASIS® Ophthalmic Emulsion and Chronic Dry Eye; an online and smart phone application of the Dry Eye patient screener, a patient Dry Eye assessment tool; and the RESTASIS® PrePro feature, providing the user wih access to—and the opportunity to provide feedback on—sections of the Web site in development. The developers of the RESTASIS® Professional Web site may add, remove, or replace the resources on the Professional Resources section at any time.
Indication and Usage: RESTASIS® Ophthalmic Emulsion is indicated to increase tear production in patients whose tear production is presumed to be suppressed due to ocular inflammation associated with keratoconjunctivitis sicca. Increased tear production was not seen in patients currently taking topical anti-inflammatory drugs or using punctal plugs.
Important Safety Information:
Contraindications: RESTASIS® is contraindicated in patients with active ocular infections and in patients with known or suspected hypersensitivity to any of the ingredients in the formulation.
Warning: RESTASIS® Ophthalmic Emulsion has not been studied in patients with a history of herpes keratitis.
Precautions: RESTASIS® should not be administered while wearing contact lenses. If contact lenses are worn, they should be removed prior to the administration of the emulsion.
Adverse Reactions: The most common adverse event was ocular burning (upon instillation) – 17%. Other events reported in 1% to 5% of patients included conjunctival hyperemia, discharge, epiphora, eye pain, foreign body sensation, pruritus, stinging, and visual disturbance (most often blurring).
Please see full prescribing information for RESTASIS® Ophthalmic Emulsion.
